Canvas Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Canvas Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-333	Closed	-$220K	–	143
2022 Q1	$220K	Sell	333 -558	-63%	-$353K	0.08%	130
2021 Q4	$563K	Sell	891 -75	-8%	-$46.1K	0.2%	87
2021 Q3	$585K	Sell	966 -40	-4%	-$24.8K	0.24%	71
2021 Q2	$562K	Buy	+1,006	New	+$510K	0.25%	71

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Canvas Wealth Advisors's REGN Position: Q2 2022 in Review

Canvas Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 333 shares — an estimated $220K sold.

Canvas Wealth Advisors first reported a position in REGN in Q2 2021 and held it in 4 quarters. The position peaked at $585K in Q3 2021. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Canvas Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Canvas Wealth Advisors sold 333 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $220K.
Canvas Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Canvas Wealth Advisors's Regeneron Pharmaceuticals position peaked at $585K in Q3 2021.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Canvas Wealth Advisors's 13F filing for Q2 2022, filed 25 Jul 2022.